Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration

[1]  M. Cenci,et al.  Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia , 2023, Cells.

[2]  J. H. Yoon,et al.  The effect of levodopa treatment on vascular endothelial function in Parkinson’s disease , 2023, Journal of Neurology.

[3]  M. Cenci,et al.  Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa‐Induced Dyskinesia , 2023, Movement disorders : official journal of the Movement Disorder Society.

[4]  P. Petersson,et al.  Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia , 2022, Neurotherapeutics.

[5]  Sam Habet.  The Clinical Pharmacology of Entacapone (Comtan®) From the Food and Drug Administration (FDA) Reviewer. , 2022, The international journal of neuropsychopharmacology.

[6]  M. Cenci,et al.  Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease , 2022, Neuropharmacology.

[7]  W. Poewe,et al.  Amantadine in the treatment of Parkinson's disease and other movement disorders , 2021, The Lancet Neurology.

[8]  M. Cenci,et al.  Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism , 2021, Neurobiology of Disease.

[9]  C. Bishop,et al.  Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia , 2021, Biomedicines.

[10]  G. Fragoso,et al.  Immunomodulatory effect and clinical outcome in Parkinson's disease patients on levodopa-pramipexole combo therapy: A two-year prospective study , 2020, Journal of Neuroimmunology.

[11]  A. Lang,et al.  Levodopa challenge test: indications, protocol, and guide , 2020, Journal of Neurology.

[12]  B. Mollenhauer,et al.  Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide , 2020, Movement disorders clinical practice.

[13]  Dopamine Agonist , 2020, Definitions.

[14]  R. Pahwa,et al.  Dyskinesia Matters , 2019, Movement disorders : official journal of the Movement Disorder Society.

[15]  K. Chaudhuri,et al.  Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease? , 2019, Movement disorders : official journal of the Movement Disorder Society.

[16]  O. Rascol,et al.  Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. , 2019, Parkinsonism & related disorders.

[17]  J. Brotchie,et al.  Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold? , 2018, The European journal of neuroscience.

[18]  M. Merello,et al.  Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study , 2018, Clinical neuropharmacology.

[19]  A. Crossman,et al.  Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[20]  L. Verhagen Metman,et al.  A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease , 2017, Clinical neuropharmacology.

[21]  F. Marotta,et al.  Current trends in etiology, prognosis and therapeutic aspects of Parkinson’s disease: a review , 2017, Acta bio-medica : Atenei Parmensis.

[22]  F. Stocchi,et al.  Advances in dopamine receptor agonists for the treatment of Parkinson’s disease , 2016, Expert opinion on pharmacotherapy.

[23]  R. Moratalla,et al.  Dopamine D3 Receptor Modulates l‐DOPA‐Induced Dyskinesia by Targeting D1 Receptor‐Mediated Striatal Signaling , 2015, Cerebral cortex.

[24]  Gilberto Fisone,et al.  Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease , 2015, Progress in Neurobiology.

[25]  A. Björklund,et al.  Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study , 2015, Brain : a journal of neurology.

[26]  F. Turkheimer,et al.  Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.

[27]  H. Reichmann,et al.  Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials , 2014, European journal of neurology.

[28]  N. Suksomboon,et al.  Meta‐analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia , 2012, Journal of clinical pharmacy and therapeutics.

[29]  M. Cenci,et al.  Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. , 2011, CNS & neurological disorders drug targets.

[30]  A. Korczyn,et al.  Gender effect on time to levodopa-induced dyskinesias , 2011, Journal of Neurology.

[31]  C. Clarke,et al.  Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[32]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[33]  M. Millan,et al.  Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease , 2009, Neurobiology of Disease.

[34]  M. Cenci,et al.  Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[35]  R. Mach,et al.  Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[36]  J. Nutt,et al.  The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile , 2008, Movement disorders : official journal of the Movement Disorder Society.

[37]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[38]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[39]  O. Rascol,et al.  Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa , 2006, Movement disorders : official journal of the Movement Disorder Society.

[40]  S. Härtter,et al.  A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. , 2006, Clinical therapeutics.

[41]  M. Youdim,et al.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.

[42]  E. Bézard,et al.  Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. , 2005, Parkinsonism & related disorders.

[43]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[44]  A Schrag,et al.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. , 2000, Brain : a journal of neurology.

[45]  S Fahn,et al.  The spectrum of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[46]  H. Widner,et al.  Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale , 1999, Movement disorders : official journal of the Movement Disorder Society.

[47]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Shippenberg,et al.  Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. , 1996, Behavioural pharmacology.

[49]  L. Bednarz,et al.  Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa. , 1995, The Journal of pharmacology and experimental therapeutics.

[50]  A. Lees,et al.  Buspirone in the treatment of levodopa induced dyskinesias. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[51]  D. Deleu,et al.  Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease , 2002, Clinical pharmacokinetics.

[52]  A. Lang,et al.  Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment , 1994, Movement disorders : official journal of the Movement Disorder Society.

[53]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[54]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[55]  A. Bazzan,et al.  [Amantadine in the treatment of Parkinson's disease]. , 1970, Il Fracastoro.